Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $29.1 million.

  • Mimedx's Free Cash Flow rose 4977.38% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 1980.81%. This contributed to the annual value of $65.4 million for FY2024, which is 9861.91% up from last year.
  • As of Q3 2025, Mimedx's Free Cash Flow stood at $29.1 million, which was up 4977.38% from $14.2 million recorded in Q2 2025.
  • Mimedx's Free Cash Flow's 5-year high stood at $29.1 million during Q3 2025, with a 5-year trough of -$11.4 million in Q4 2021.
  • Moreover, its 5-year median value for Free Cash Flow was $5.6 million (2024), whereas its average is $6.0 million.
  • In the last 5 years, Mimedx's Free Cash Flow plummeted by 38350.08% in 2022 and then skyrocketed by 194459.02% in 2023.
  • Over the past 5 years, Mimedx's Free Cash Flow (Quarter) stood at -$11.4 million in 2021, then surged by 45.05% to -$6.3 million in 2022, then skyrocketed by 240.57% to $8.8 million in 2023, then soared by 109.41% to $18.5 million in 2024, then skyrocketed by 57.34% to $29.1 million in 2025.
  • Its Free Cash Flow stands at $29.1 million for Q3 2025, versus $14.2 million for Q2 2025 and $4.9 million for Q1 2025.